Exploration and Characterization Ofintratumoral Electrophysiological Heterogeneity in Gliomas Using Magnetoencephalography (GLIOMEG)

May 27, 2026 updated by: Hospices Civils de Lyon

With more than 3,000 new cases per year in France, malignant gliomas are the most common malignant brain tumors in adults.

Treatment consists of surgical removal when possible. If this is not possible, a biopsy is performed to obtain a definitive anatomical and molecular diagnosis. Standard medical management after removal or biopsy is based on radio-chemotherapy. Despite this multimodal treatment, progression is the norm due to the invasive nature of these tumors. The prognosis remains very poor, with a median overall survival of around 18 months for glioblastomas.

Recent preliminary data indicate that magnetoencephalography (MEG) recordings can identify functional heterogeneity within a glioma. Functional analysis of these two types of areas has shown that the expression of synaptogenic factors is increased in areas of high functional connectivity compared to areas of low functional connectivity. Areas of high functional connectivity are more aggressive and more resistant to treatment.

In general, gliomas are characterized by a high degree of inter- and intra-tumoral heterogeneity. The latter has been well characterized at the transcriptomic level, and several distinct cell subpopulations have been described (classical, mesenchymal, proneural) This intra-tumoral heterogeneity is one of the factors contributing to resistance to current therapies, but it remains incompletely understood and explored. MEG is a tool capable of exploring intra- and inter-tumor heterogeneity from an electrophysiological perspective. This represents an original approach that will provide a better understanding of intra-tumor heterogeneity and lead to new therapeutic perspectives.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male or female aged over 18
  • With a newly diagnosed malignant glioma based on brain imaging
  • Eligible for surgical removal
  • Having given their consent

Exclusion Criteria:

  • Contraindications to Magnetic resonance imaging (MRI) (claustrophobia, metallic implants, particularly intraocular implants, pacemakers)
  • Contraindications to magnetoencephalography (MEG) (metallic implants in the mouth-dentures, fillings, crowns)
  • Coagulation disorders
  • Pregnancy, breastfeeding, or patients not using effective contraception
  • Subjects participating in another interventional study with an exclusion period still in progress at the time of pre-inclusion, etc.
  • Subjects deprived of their liberty by judicial or administrative decision
  • Subjects receiving psychiatric care
  • Subjects admitted to a health or social care facility for purposes other than research
  • Adult subjects subject to legal protection measures (guardianship, curatorship)
  • Subjects not affiliated with a social security system or beneficiaries of a similar system

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: magnetoencephalography (MEG)
Every patients eligible for a glioma resection surgery
Device: MEG
Eligible patients will undergo a complete Magnetoencephalography, of approximatively 45min

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assess the technical feasibility of studying tumor electrophysiological heterogeneity using magnetoencephalography (MEG) in a series of patients with glioma at the initial stage of treatment.
Time Frame: At baseline and during the 10 days prior to the date of surgery, according to the standard of care.
Percentage of patients with a complete and usable magnetoencephalography (MEG) recording, allowing intra- and peri-tumoral electrophysiological data to be collected and resting functional connectivity to be studied for all areas of the brain.
At baseline and during the 10 days prior to the date of surgery, according to the standard of care.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Define the radiological characteristics of the different types of areas of interest identified by MEG by comparing MEG mapping and preoperative MRI (anatomical and functional).
Time Frame: At baseline and during the 10 days prior to the date of surgery, according to the standard of care.
Radiological patterns of areas identified by MEG, based on preoperative brain Magnetic resonance imaging (MRI) (morphological and functional)
At baseline and during the 10 days prior to the date of surgery, according to the standard of care.
Define the prognostic impact of ablation of areas with different electrophysiological properties, using an analysis that integrates MEG mapping data, post-operative MRI data, and survival data.
Time Frame: At baseline and during the 10 days prior to the date of surgery, according to the standard of care.
Survival of patients with residual High Frequency Channel/ Low Frequency Channel (HFC/LFC) areas on postoperative MRI and survival of patients without such areas.
At baseline and during the 10 days prior to the date of surgery, according to the standard of care.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospices Civils de Lyon

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 1, 2026

Primary Completion (Estimated)

July 1, 2029

Study Completion (Estimated)

December 1, 2029

Study Registration Dates

First Submitted

May 18, 2026

First Submitted That Met QC Criteria

May 27, 2026

First Posted (Actual)

June 1, 2026

Study Record Updates

Last Update Posted (Actual)

June 1, 2026

Last Update Submitted That Met QC Criteria

May 27, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 69HCL26_0020
  • 2026-A01156-45 (Other Identifier: ID-RCB)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Patients Diagnosed With a Malignant Glioma

Clinical Trials on MEG

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe